Carbohydrate mimics and lectins: A source of new drugs and therapeutic opportunities

Mini-Reviews in Medicinal Chemistry

Volumn 12, Issue 14, 2012, Pages 1434-1442

  Reina, José J ^a   Bernardi, Anna ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

C type lectins and DC SIGN; Carbohydrates; Glycomimetics

Indexed keywords

CARBOHYDRATE DERIVATIVE; CD209 ANTIGEN; DENDRIMER; INTERCELLULAR ADHESION MOLECULE 3; LECTIN; MANNOSE; OLIGOSACCHARIDE; SCAFFOLD PROTEIN;

DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG STABILITY; DRUG SUBSTITUTION; IC 50; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; BIOMIMETIC MATERIALS; BIOMIMETICS; CARBOHYDRATES; CELL ADHESION MOLECULES; DRUG DISCOVERY; HUMANS; LECTINS; LECTINS, C-TYPE; MODELS, MOLECULAR; RECEPTORS, CELL SURFACE;

EID: 84873209047     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955712803832690     Document Type: Review

References (104)

1. Kamerling, J. P. Comprehensive Glycoscience. From Chemistry to System Biology, Vols. 3 and 4, Elsevier, Amsterdam, 2007.
2. Gabius, H.-J.; André, S.; Jiménez-Barbero, J.; Romero, A.; Sols, D. From lectin structure to functional glycomics: principles of the sugar code. Trends in Biochemical Sciences, 2011, 36, 298-313.
3. Gabius, H.-J.; Siebert, H.-C.; André, S.; Jiménez-Barbero, J.; Rüdiger, H. Chemical Biology of the Sugar Code. Chem. Bio. Chem., 2004, 5, 740-764.
4. Structural Medicine: The Importance of Glycomics for Health and Disease, European Science Foundation, Strasbourg, 2006.
5. Werz, D. B., Seeberger P. H. in Chemical Biology: From Small Molecules to Systems Biology and Drug Design (Eds.: S. L. Schreiber, T. M. Kapoor, G. Wess) Wiley-VCH, Weinheim, 2007, 668-691.
6. Pilobello, K. T.; Mahal, L. K. Deciphering the glycocode: the complexity and analytical challenge of glycomics. Curr. Opin. Chem. Biol., 2007, 11, 300-305.
7. Paulson, J. C.; Blixt, O.; Collins, B. E. Sweet spots in functional glycomics. Nat. Chem. Biol., 2006, 2, 238-248.
8. Luetteke, T.; Bohne-Lang, A.; Loss, A.; Goetz, T.; Frank, M.; von der Lieth, C.-W. GLYCOSCIENCES. de: an Internet portal to support glycomics and glycobiology research. Glycobiology, 2006, 16, 71R-81R.
9. Bertozzi, C. R.; Kiessling, L. L. Chemical Glycobiology. Science, 2001, 291, 2357-2364.
10. Culf, A. S.; Cuperlovic-Culf, M.; Ouellette, R. J. Carbohydrate Microarrays: Survey of Fabrication Techniques. OMICS, 2006, 10, 289-310.
11. Turnbull, J. E.; Field, R. A. Emerging glycomics technologies. Nat Chem. Biol., 2007, 3, 74-77.
12. von der Lieth, C.-W.; Ardá Freire, A.; Blank, D.; Campbell, M. P.; Ceroni, A.; Damerell, D. R.; Dell, A.; Dwek, R. A.; Ernst, B.; Fogh, R.; Frank, M.; Geyer, H.; Geyer, R.; Harrison, M. J.; Henrick, K.; Herget, S.; Hull, W.E.; Ionides, J.; Joshi, H. J.; Kamerling, J. P.; Leeflang, B. R.; Lütteke, T.; Lundborg, M.; Maass, K.; Merry, A.; Ranzinger, R.; Rosen, J.; Royle, L.; Rudd, P. M.; Schloissnig, S.; Stenutz, R.; Vranken, W. F.; Widmalm, G.; Haslam, S. M. EUROCarbDB: An open-access platform for glycoinformatics. Glycobiology, 2011, 21, 493-502.
13. see http://www.eurocarbdb.org and links therein.
14. Werz, D.B.; Ranzinger, R.; Herget, S.; Adibekian, A.; vonder Lieth, C.-W.; Seeberger P.H. Exploring the Structural Diversity of Mammalian Carbohydrates ("Glycospace") by Statistical Databank Analysis. ACS Chem. Biol., 2007, 2, 685-691.
15. Ernst, B.; Magnani, J. L. From carbohydrate leads to glycomimetic drugs. Nat. Rev. Drugs Discovery, 2009, 8, 661-677.
16. Cheshev, P.; Bernardi, A. Interfering with the Sugar Code: Design and Synthesis of Oligosaccharide Mimics. Chem. Eur. J., 2008, 14, 7434-7441.
17. Winchester, B.; Fleet, G.W.J. Amino-sugar glycosidase inhibitors: versatile tools for glycobiologists. Glycobiology, 1992, 2, 199-210.
18. Pearson, M.S.M.; Mathé-Allainmat, M.; Fargeas, V.; Lebreton, J. Recent Advances in the Total Synthesis of Piperidine Azasugars. Eur. J. Org. Chem., 2005, 2159-2191 and references therein.
19. Nishimura, Y. in Iminosugars: From Synthesis to Therapeutic Applications, ed. P. Compain and O. R. Martin, Wiley-VCH, Weinheim, Germany, 2007, p 269
20. Aguilar-Moncayo, M.; Garcia-Moreno, M. I.; Trapero, A.; Egido-Gabas, M.; Llebaria, A.; Garcia Fernandez, J. M.; Ortiz, C. Bicyclic (galacto)nojirimycin analogues as glycosidase inhibitors: Effect of structural modifications in their pharmacological chaperone potential towards β-glucocerebrosidase. Org. Biomol. Chem., 2011, 9, 3698-3713 and references therein.
21. von Itzstein, M. The war against influenza: discovery and development of sialidase inhibitors. Nat. Rev. Drug Discovery, 2007, 6, 967-974.
22. Gross, B.J.; Swoboda, J. G.; Walker, S. A Strategy to Discover Inhibitors of O-Linked Glycosylation. J. Am. Chem. Soc., 2008, 130, 440-441.
23. Ghazarian, H.; Idoni, B.; Oppenheimer, S. B. A glycobiology review: Carbohydrates, lectins and implications in cancer therapeutics. Acta Histochemica, 2011, 113, 236-247.
24. Weis W. I.; Taylor M. E.; Drickamer, K. The C-type lectin superfamily in the immune system. Immunol. Rev., 1998, 163, 19-34.
25. Gabius, H.J.; Andre, S.; Kaltner, H.; Siebert H. C. The sugar code: functional lectinomics. Biochem. Biophys. Acta, 2002, 1572, 165-177.
26. Pieters, R. J. Inhibition and Detection of Galectins. ChemBioChem, 2006, 7, 721-728.
27. Sharon, N.; Lis, H. History of lectins: from hemagglutinins to biological recognition molecules. Glycobiology, 2004, 14, 53R-62R.
28. Sanchez-Ruderisch, H.; Fischer, C.; Detjen, K. M.; Welzel, M.; Wimmel, A.; Manning, J. C.; Andre, S.; Gabius, H.-J. Tumor suppressor p16 INK4a: Downregulation of galectin-3, an endogenous competitor of the pro-anoikis effector galectin-1, in a pancreatic carcinoma model. FEBS J., 2010, 277, 3552-3563.
29. Cipolla, L.; Araijo, A. C.; Bini, D.; Gabrielli, L.; Russo, L.; Shaikh, N. Discovery and design of carbohydrate-based therapeutics. Expert. Opin. Drug Discov., 2010, 5, 721-737.
30. Cipolla, L.; La Ferla, B.; Airoldi, C.; Zona, C.; Orsato, A.; Shaikh, N.; Russo, L.; Nicotra, F. Carbohydrate Mimetics and Scaffolds: Sweet Spots in Medicinal Chemistry. Fut. Med. Chem., 2010, 2, 587-599.
31. Varki, A. Biological roles of oligosaccharides: all of the theories are correct. Glycobiology, 1993, 3, 97-130.
32. Dwek, R. A. Glycobiology: Toward Understanding the Function of Sugars. Chem. Rev., 1996, 96, 683-720.
33. Lee, Y. C.; Lee, R. T. Carbohydrate-Protein Interactions: Basis of Glycobiology. Acc. Chem. Res., 1995, 28, 321-327.
34. Seeberger, P. H.; Werz, D. B. Synthesis and medical applications of oligosaccharides. Nature, 2007, 446, 1046-1051.
35. Aplander, K.; Marttila, M.; Manner, S.; Arnberg, N.; Sterner, O.; Ellervik, U. Molecular wipes: application to epidemic keratoconjuctivitis. J. Med. Chem., 2011, 54, 6670-6675.
36. Roldos, V.; Canada, F. J.; Jiménez-Barbero, J. Carbohydrateprotein interactions: a 3D view by NMR. ChemBioChem, 2011, 12, 990-1005.
37. Binder, F.P.C.; Ernst, B. E-and P-Selectin: Differences, Similarities and Implications for the Design of P-Selectin Antagonists. Chimia, 2011, 65, 210-213.
38. Cheshev, P.; Morelli, L.; Marchesi, M.; Podlipnik, C.; Bergstrom, M.; Bernardi, A. Synthesis and Affinity Evaluation of a Small Library of Bidentate Cholera Toxin Ligands: Towards Nonhydrolyzable Ganglioside Mimics. Chemistry Eur. J., 2010, 16, 1951-1967.
39. Tran, H.-A.; Kitov, P. I.; Paszkiewicz, E.; Sadowska, J. M.; Bundle, D. Multifunctional multivalency: a focused library of polymeric cholera toxin antagonists. Org. Biomol. Chem., 2011, 9, 3658-3671.
40. Klein, T.; Abgottspon, D.; Wittwer, M.; Rabbani, S.; Herold, J.; Jiang, X. H.; Kleeb, S.; Luthi, C.; Scharenberg, M.; Bezencon, J.; Gubler, E.; Pang, L.J.; Smiesko, M.; Cutting, B.; Schwardt, O.; Ernst, B. FimH Antagonists for the Oral Treatment of Urinary Tract Infections: From Design and Synthesis to In Vitro and In Vivo Evaluation. J. Med. Chem., 2010, 53, 6670-6675.
41. Schwardt, O.; Rabbani, S.; Hartmann, M.; Abgottspon, D.; Wittwer, M.; Kleeb, S.; Zalewski, A.; Smiesko, M.; Cutting, B.; Ernst, B. Design, Synthesis and Biological Evaluation of Mannosyl Triazoles as FimH Antagonists Bioorg. Med. Chem., 2011, 19, 6454-6473.
42. Hartmann M.; Lindhorst T. K. The Bacterial Lectin FimH, a Target for Drug Discovery-Carbohydrate Inhibitors of Type 1 Fimbriae-Mediated Bacterial Adhesion. Eur. J. Org. Chem., 2011, 3583-3609 and references therein.
43. Mesch, S.; Lemme, K.; Wittwer, M.; Koliwer-Brandl, H.; Schwardt, O.; Kelm, S.; Ernst, B. From a Library of MAG Antagonists to Nanomolar CD22 Ligands. ChemMedChem, 2012, 7, 134-143.
44. Zeng, Y.; Rademacher, C.; Nycholat, C. M.; Futakama, S.; Lemme, K.; Ernst, B. High affinity sialoside ligands of myelin associated glycoprotein. Bioorg. Med. Chem. Lett., 2011, 21, 5045-5049.
45. Schwardt, O.; Koliwer-Brandl, H.; Zimmerli, R.; Mesch, S.; Rossato, G.; Spreafico, M.; Vedani, A.; Kelm, S.; Ernst B. Design, synthesis, biological evaluation and modeling of a non-carbohydrate antagonist of the myelin-associated glycoprotein Bioorg. Med. Chem., 2010, 18, 7239-7251.
46. Chambre, Y. M.; Giguere, D.; Blanchard, B.; Rodriguez, J.; Rocheleau, S.; Neault, M.; Rauthu, S.; Papadopoulos, A.; Arnold, A. A.; Imberty, A.; Roy, R. Combining Glycomimetic and Multivalent Strategies toward Designing Potent Bacterial Lectin Inhibitors. Chem. Eur. J., 2011, 17, 6545-6562.
47. Geijtenbeek, T. B. H.; Torensma, R.; Van Vliet, S. J.; van Duijnhoven, G. C.; F., Adema, G. J.; van Kooyk, Y.; Figdor, C. G. Identification of DC-SIGN, a Novel Dendritic Cell-Specific ICAM-3 Receptor that Supports Primary Immune Responses Cell, 2000, 100, 575-585.
48. Yuasa, H.; Izumi, M.; Hashimoto, H. Thiasugars: potential glycosidase inhibitors. Curr. Top. Med. Chem., 2009, 9, 76-86.
49. Arjona, O.; Gómez, A. M.; López, J. C.; Plumet, J. Synthesis and conformational and biological aspects of carbasugars. Chem. Rev., 2007, 107, 1919-2036.
50. Koester, D. C.; Holkenbrink, A.; Werz, D. B. Recent Advances in the Synthesis of Carbohydrate Mimetics. Synthesis, 2010, 19, 3217-3242 and references cited therein.
51. Lindhorst, T. K. Artificial Multivalent Sugar Ligands to Understand and Manipulate Carbohydrate-Protein Interactions. Top. Curr. Chem., 2002, 218, 201-235.
52. Pieters, R. J. Interference with Lectin Binding and Bacterial Adhesion by Multivalent Carbohydrates and Peptidic Carbohydrate Mimics. Trends Glycosci. Glycotechnol., 2004, 16, 243-244.
53. Ohlsen, K.; Oelschlaeger, T. A.; Hacker, J.; Khan, A. S. Carbohydrate receptors of bacterial adhesins: implications and reflections. Top. Curr. Chem., 2009, 288, 17-65.
54. Chabre, Y. M.; Roy, R. Recent trends in glycodendrimer syntheses and applications. Curr. Top. Med. Chem., 2008, 8, 1237-1285.
55. Kalia, N.; Janz, K.; DeBernardo, S.; Bedard, P. W.; Camphausen, R. T.; Tam, S.; Tsao, D. H. H.; Keith, J. C.; Nickerson-Nutter, C.; Shilling, A.; Young-Sciame, R.; Wang, Q. Synthesis and Biological Evaluation of Quinoline Salicylic Acids As P-Selectin Antagonists. J. Med. Chem., 2007, 50, 21-39.
56. Kalia, N.; Janz, K.; Huang, A.; Moretto, A.; DeBernardo, S.; Bedard, P. W.; Tam, S.; Clerin, V.; Keith, J. C.; Tsao, D. H. H.; Sushkova, N.; Shaw, G. D.; Camphausen, R. T.; Schaub, R. G.; Wang, Q. 2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[H] quinoline-4-carboxylic Acid (PSI-697): Identification of a Clinical Candidate from the Quinoline Salicylic Acid Series of P-Selectin Antagonists. J. Med. Chem., 2007, 50, 40-64.
57. Borrok, M. J.; Kiessling, L. L. Non-Carbohydrate Inhibitors of the Lectin DC-SIGN. J. Am. Chem. Soc., 2007, 129, 12780-12785.
58. Bhunia, A.; Schwardt, O.; Gathje, H.; Gao, G. P.; Kelm, S.; Benie, A. J.; Hricovini, M.; Peters, T.; Ernst, B. Consistent Bioactive Conformation of the Neu5Ac_(2_3)Gal Epitope Upon Lectin Binding. ChemBioChem, 2008, 9, 2941-2945.
59. Roseman, S. Reflections on glycobiology. J. Biol. Chem., 2001, 276, 41527-41542.
60. Brocca, P.; Bernardi, A.; Raimondi, L.; Sonnino, S. Modeling ganglioside headgroups by conformational analysis and molecular dynamics. Glycoconjugate J., 2000, 17, 283-299.
61. Yuriev, E.; Farrugia, W.; Scott, A.M.; Ramsland, P.A. Threedimensional structures of carbohydrate determinants of Lewis system antigens: Implications for effective antibody targeting of cancer. Immunol. Cell Biol., 2005, 83, 709-717.
62. Jiménez-Barbero, J.; Asensio, J. L.; Cañada, F. J.; Poveda, A. Free and protein-bound carbohydrate structures. Curr. Opin. Struct. Biol., 1999, 9, 549-555.
63. Mammen, M.; Choi, S.-K.; Whitesides, G. M. Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors. Angew. Chem. Int. Ed., 1998, 37, 2755-2794.
64. Kitov, P. I.; Sadowska, J. M.; Mulvey, G.; Armstrong, G. D.; Ling, H.; Pannu, N. S.; Read, R. J.; Bundle, D. R. Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature, 2000, 403, 669-672.
65. Fan, E. K.; Zhang, Z. S.; Minke, W. E.; Hou, Z.; Verlinde, C. L. M. J.; Hol, W. G. J. High-affinity pentavalent ligands of Escherichia coli heat-labile enterotoxin by modular structure-based design. J. Am. Chem. Soc., 2000, 122, 2663-2664.
66. Arosio, D.; Fontanella, M.; Baldini, L.; Mauri, L; Bernardi, A.; Casnati, A.; Sansone, F.; Ungaro, R. A Synthetic Divalent Cholera Toxin Glycocalix[4]arene Ligand Having Higher Affinity than Natural GM1 Oligosaccharide. J. Am. Chem. Soc., 2005, 127, 3660-3661.
67. Pukin, A. V.; Branderhorst, H. M.; Sisu, C.; Weijers, C. A. G. M.; Gilbert, M.; Liskamp, R. M. J.; Visser, G. M.; Zuilhof, H.; Pieters, R. J. Strong Inhibition of Cholera Toxin by Multivalent GM1 Derivatives. ChemBioChem, 2007, 8, 1500-1503.
68. Tabarani, G.;Thepaut, M.; Stroebel, D.; Ebel, C.; Vives, P.; Vachette, P.; Duramd, D.; Fieschi, F. DC-SIGN Neck Domain Is a pH-sensor Controlling Oligomerization. J. Biol. Chem., 2009, 284, 21229-21240.
69. Serrano-Sierra-Gomez, D.; Sierra-Filardi, E.; Martinez-Nuñez, E. T.; Caparros, E.; Delgado, R.; Muñoz-Fernandez, A.; Abad, M. A.; Jiménez-Barbero, J.; Leal, M.; Corbi, A. L. Structural Requirements for Multimerization of the Pathogen Receptor Dendritic Cell-specific ICAM3-grabbing Non-integrin (CD209) on the Cell Surface. J. Biol. Chem., 2008, 283, 3889-3903.
70. Feinberg, H.; Guo, Y.; Mitchell, D. A.; Drickamer, K.; Weis, W. I. Extended Neck Regions Stabilize Tetramers of the Receptors DC-SIGN and DC-SIGNR. J. Biol. Chem., 2005, 280, 1327-1335.
71. Mitchell, D. A.; Fadden, A. J.; Drickamer, K. A novel mechanism of carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR: subunit organization and binding to multivalent ligands. J. Biol. Chem., 2001, 276, 28939-28945.
72. Geijtenbeek, T. B. H.; Kwon, D. S.; Torensma, R.; Van Vliet, S. J.; van Duijnhoven, G. C. F.; Middel, J.; Cornelissen, I. L. M. H. A.; Nottet, H. S. L. M.; Kewal Ramani, V. N.; Littman, D. R.; Figdor, C. G.; van Kooyk, Y. DC-SIGN, a Dendritic Cell-Specific HIV-1-Binding Protein that Enhances trans-Infection of T Cells. Cell, 2000, 100, 587-597.
73. Lozach, P.-Y.; Lortat-Jacob, H.; De Lacroix De Lavalette, A.; Staropoli, I.; Foung, S.; Amara, A.; Houles, C.; Fieschi, F.; Schwartz, O.; Virelizier, J.-L.; Arenzana-Seisdedos, F.; Altmeyer, R. DC-SIGN and L-SIGN Are High Affinity Binding Receptors for Hepatitis C Virus Glycoprotein E2. J. Biol. Chem., 2003, 278, 20358-20366.
74. Alvarez, C. P.; Lasala, F.; Carrillo, J.; Muniz, O.; Corbi, A. L.; Delgado, R. C-Type Lectins DC-SIGN and L-SIGN Mediate Cellular Entry by Ebola Virus in cis and in trans. J. Virol., 2002, 76, 6841-6844.
75. Han, D. P.; Lohani, M.; Cho, M. W. Specific Asparagine-Linked Glycosylation Sites Are Critical for DC-SIGN-and L-SIGNMediated Severe Acute Respiratory Syndrome Coronavirus Entry. J. Virol., 2007, 81, 12029-12039.
76. Tailleux, L.; Schwartz, O.; Herrmann, J. L.; Pivert, E.; Jackson, M.; Amara, A.; Legres, L.; Dreher, D.; Nicod, L. P.; Gluckman, J. C.; Lagrange, P. H.; Gicquel, B.; Neyrolles, O. DC-SIGN Is the Major Mycobacterium tuberculosis Receptor on Human Dendritic Cells. J. Exp. Med., 2003, 197, 121-127.
77. Kang, Y. S.; Kim, J. Y.; Bruening, S. A.; Pack, M.; Charalambous, A.; Pritsker, A.; Moran, T. M.; Loeffler, J. M.; Steinman, R. M.; Park, C. G. The C-type lectin SIGN-R1 mediates uptake of the capsular polysaccharide of Streptococcus pneumoniae in the marginal zone of mouse spleen. Proc. Natl. Acad. Sci., 2004, 101, 215-220.
78. Cambi, A.; Gijzen, K.; de Vries, J. M.; Torensma, R.; Joosten, B.; Adema, G. J.; Netea, M. G.; Kullberg, B. J.; Romani, L.; Figdor, C. G. The C-type lectin DC-SIGN (CD209) is an antigen-uptake receptor for Candida albicans on dendritic cells. Eur. J. Immunol., 2003, 33, 532-538.
79. Serrano-Gomez, D.; Dominguez-Soto, A.; Ancochea, J.; Jimenez-Heffernan, J. A.; Leal, J. A.; Corbi, A. L. Dendritic Cell-Specific Intercellular Adhesion Molecule 3-Grabbing Nonintegrin Mediates Binding and Internalization of Aspergillus fumigatus Conidia by Dendritic Cells and Macrophages. J. Immunol., 2004, 173, 5635-5643.
80. Colmenares, M.; Puig-Kroger, A.; Pello, O. M.; Corbi, A. L.; Rivas, L. Dendritic Cell (DC)-specific Intercellular Adhesion Molecule 3 (ICAM-3)-grabbing Nonintegrin (DC-SIGN, CD209), a C-type Surface Lectin in Human DCs, Is a Receptor for Leishmania Amastigotes. J. Biol. Chem., 2002, 277, 36766-36769.
81. van Die, I.; van Vliet, S. J.; Nyame, A. K.; Cummings, R. D.; Bank, C. M. C.; Appelmelk, B.; Geijtenbeek, T. B. H.; van Kooyk, Y. The dendritic cell-specific C-type lectin DC-SIGN is a receptor for Schistosoma mansoni egg antigens and recognizes the glycan antigen Lewis-x. Glycobiology, 2003, 13, 471-478.
82. Reina, J. J.; Bernardi, A.; Clerici, M.; Rojo, J. HIV microbicides: state of the art and new perspectives on the development of entry inhibitors. Fut. Med. Chem., 2010, 2, 1141-1159 and references cited therein.
83. Sánchez-Navarro, M.; Rojo J. Targeting DC-SIGN with carbohydrate multivalent systems. Drugs News & Perspectives, 2010, 23, 557-572.
84. Feinberg, H.; Castelli, R.; Drickamer, K.; Seeberger, P. H.; Weis, W. I. Multiple Modes of Binding Enhance the Affinity of DC-SIGN for High Mannose N-Linked Glycans Found on Viral Glycoproteins. J. Biol. Chem., 2007, 282, 4202-4209.
85. Guo, Y.; Feinberg, H.; Conroy, E.; Mitchell, D. A.; Alvarez, R.; Blixt, O.; Taylor, M. E.; Weis, W. I.; Drickamer, K. Structural basis for distinct ligand-binding and targeting properties of the receptors DC-SIGN and DC-SIGNR. Nat. Struct. Mol. Biol., 2004, 11, 591-598.
86. Feinberg, H.; Mitchell, D. A.; Drickamer, K.; Weis, W. I. Structural Basis for Selective Recognition of Oligosaccharides by DC-SIGN and DC-SIGNR. Science, 2001, 294, 2163-2166.
87. Reina, J.J.; Sattin, S.; Invernizzi, D.; Mari, S.; Martinez-Prats, L.; Tabarani, G.; Fieschi, F.; Delgado, R.; Nieto, P.M.; Rojo, J.; Bernardi, A. 1,2-Mannobioside Mimic: Synthesis, DC-SIGN Interaction by NMR and Docking, and Antiviral Activity. Chem. Med. Chem, 2007, 2, 1030-1036.
88. Adams, E. W.; Ratner, D. M.; Bokesch, H. R.; McMahon, J. B.; O'Keefe, B. R.; Seeberger, P. H. Oligosaccharide and Glycoprotein Microarrays as Tools in HIV Glycobiology: Glycan-Dependent gp120/Protein Interactions. Chem. Biol., 2004, 11, 875-881.
89. Mari, S.; Posteri, H.; Marcou, G.; Potenza, D.; Micheli, F.; Cañada, F. J.; Jiménez-Barbero, J.; Bernardi, A. The conformational behavior of novel glycosidase inhibitors with substituted azepan structures. A NMR and modeling study. Eur. J. Org. Chem., 2004, 5119-5125.
90. Mari, S.; Sánchez-Medina, I.; Mereghetti, P.; Belvisi, L.; Jiménez-Barbero, J.; Bernardi, A. Synthesis and Conformational Analysis of a β-Man-(1_2)-β-Man-(1_6)-β-Man Mimic. Carb. Res., 2007, 342, 1859-1868.
91. Sattin, S.; Daghetti, A.; Thépaut, M.; Berzi, A.; Sánchez-Navarro, M.; Tabarani, G.; Rojo, J.; Fieschi, F.; Clerici, M.; Bernardi, A. Inhibition of DC-SIGN-mediated HIV infection by a linear trimannoside mimic in a tetravalent presentation. ACS Chem. Biol., 2010, 5, 301-312.
92. Luczkowiak, J.; Sattin, S.; Sutkeviciute, I.; Reina, J. J.; Sánchez-Navarro, M.; Thépaut, M.; Martínez-Prats, L.; Daghetti, A.; Fieschi, F.; Delgado, R.; Bernardi, A.; Rojo, J. Pseudosaccharide functionalized dendrimers as potent inhibitors of DC-SIGN dependent Ebola pseudotyped viral infection. Bioconjugate Chem., 2011, 22, 1354-1365.
93. Lasala, F.; Arce, E.; Otero, J. R.; Rojo, J.; Delgado, R. Mannosyl Glycodendritic Structure Inhibits DC-SIGN-Mediated Ebola Virus Infection in cis and in trans. Antimicrob. Agents Chemother., 2003, 47, 3970-3972.
94. Obermajer, N.; Sattin, S.; Colombo, C.; Bruno, M.; Svajger, U.; Anderluh, M.; Bernardi, A. Design, synthesis and activity evaluation of mannose-based DC-SIGN antagonists. Mol. Div., 2011, 15, 347-360.
95. Varga, N. et al., manuscript in preparation.
96. Crystal Structure of DC-SIGN carbohydrate recognition domain complexed with Man4. Protein Data Bank. http://www.pdb.org/pdb/explore/explore.do?structureId=1SL4. (Accessed 6 July 2009)
97. Schuster, M. C.; Mann, D. A.; Buchholz, T. J.; Johnson, K. M.; Thomas, W. D.; Kiessling, L. L. Parallel synthesis of glycomimetic libraries: targeting a C-type lectin. Org. Lett., 2003, 5, 1407-1410.
98. Garber, K. C. A.; Wangkanont, K.; Carlson, E. E.; Kiessling, L. L. A general glycomimetic strategy yields non-carbohydrate inhibitors of DC-SIGN. Chem. Comm., 2010, 46, 6747-6749.
99. Courtney, A. H.; Puffer, E. B.; Pontrello, J. K.; Yang Z. Q.; Kiessling, L. L. Sialylated multivalent antigens engage CD22 in trans and inhibit B cell activation. Proc. Natl. Acad. Sci. USA, 2009, 106, 2500-2505.
100. Kiessling, L. L.; Splain, R. A. Chemical Approaches to Glycobiology. Annu. Rev. Biochem., 2010, 79, 619-653.
101. Bielawski, C. W.; Grubbs, R. H. Living ring-opening metathesis polymerization. Progress in Polymer Science, 2007, 32, 1-29.
102. Timpano, G.; Tabarani, G.; Anderluh, M.; Invernizzi, D.; Vasile, F.; Potenza, D.; Nieto, P. M.; Rojo, J.; Fieschi, F.; Bernardi, A. Synthesis of Novel DC-SIGN Ligands with an β-Fucosylamide Anchor. ChemBioChem, 2008, 9, 1921-1930.
103. Andreini, M.; Doknic, D.; Sutkeviciute, I.; Reina, J. J.; Duan, J. X.; Chabrol, E.; Thepaut, M.; Moroni, E.; Doro, F.; Belvisi, L.; Weiser, J.; Rojo, J.; Fieschi, F.; Bernardi, A. Second generation of Fucosebased DC-SIGN ligands: affinity improvement and specificity versus Langerin. Org. Biomol. Chem., 2011, 9, 5778-5786.
104. Obermajer, N.; Svajger, U.; Jeras, M.; Sattin, S.; Bernardi, A.; Anderluh, M. An assay for functional dendritic cell-specific ICAM-3-grabbing nonintegrin (DC-SIGN) inhibitors of human dendritic cell adhesion. Anal. Biochem., 2010, 406, 222-229.